Mar. 29, 2023
SEQ-9
oral Mtb 23S bacterial ribosome inhibitor potent in vitro + in vivo activity against Mycobacterium tuberculosis opt. of sequanamycin macrolides Cell, February 23, 2023 Sanofi, FR +CH
oral Mtb 23S bacterial ribosome inhibitor potent in vitro + in vivo activity against Mycobacterium tuberculosis opt. of sequanamycin macrolides Cell, February 23, 2023 Sanofi, FR +CH